McMullan, Christel http://orcid.org/0000-0002-0878-1513
Retzer, Ameeta
Hughes, Sarah E.
Aiyegbusi, Olalekan Lee
Bathurst, Camilla
Boyd, Alan
Coleman, Jamie
Davies, Elin Haf
Denniston, Alastair K.
Dunster, Helen
Frost, Chris
Harding, Rosie
Hunn, Amanda
Kyte, Derek
Malpass, Rebecca
McNamara, Gary
Mitchell, Sandra
Mittal, Saloni
Newsome, Philip N.
Price, Gary
Rowe, Anna
van Reil, Wilma
Walker, Anita
Wilson, Roger
Calvert, Melanie
Clinical trials referenced in this document:
Documents that mention this clinical trial
Feasibility of a new electronic patient-reported outcome (ePRO) system for an advanced therapy clinical trial in immune-mediated inflammatory disease (PROmics): protocol for a qualitative feasibility study
https://doi.org/10.1136/bmjopen-2022-063199
Development and usability testing of an electronic patient-reported outcome (ePRO) solution for patients with inflammatory diseases in an Advanced Therapy Medicinal Product (ATMP) basket trial
https://doi.org/10.1186/s41687-023-00634-3
Funding for this research was provided by:
UK Research and Innovation (IUK: 104777)
UK Research and Innovation (IUK: 104232)
Article History
Received: 9 August 2022
Accepted: 10 September 2023
First Online: 9 October 2023
Declarations
:
: Usability testing was approved by the University of Birmingham Research Ethics committee (ERN_19-1271).
: Not required.
: CM receives funding from NIHR Surgical Reconstruction and Microbiology Research Centre (SRMRC), UKRI, and declares personal fees from Aparito Ltd outside the submitted work. SEH is supported by the National Institute for Health Research (NIHR) Applied Research Centre (ARC) West Midlands at the University of Birmingham and UKRI. SEH has received personal fees from Cochlear Ltd and Aparito Ltd outside the submitted work. OLA receives funding from the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, NIHR ARC West Midlands at the University of Birmingham, the Brain Tumour Charity, Innovate UK (part of UK Research and Innovation), Gilead Sciences Ltd. and Janssen Pharmaceuticals Inc. OLA declares personal fees from Gilead Sciences Ltd., GlaxoSmithKline (GSK) and Merck outside the submitted work. MC is a National Institute for Health Research (NIHR) Senior Investigator and receives funding from the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, the NIHR Surgical Reconstruction and Microbiology Research Centre and NIHR ARC West Midlands at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Health Data Research UK, UKRI, Macmillan Cancer Support, UCB Pharma, Gilead, Janssen and GSK. MC has received personal fees from Astellas, Aparito Ltd, CIS Oncology, Takeda, Merck, Daiichi Sankyo, Glaukos, GSK and the Patient-Centred Outcomes Research Institute (PCORI) outside the submitted work. DK reports grants from Macmillan Cancer Support, the NIHR, NIHR Birmingham Biomedical Research Centre, and NIHR SRMRC at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, and personal fees from Merck and GSK outside the submitted work.